Salud financiera de hoja de balance de Avenue Therapeutics

Salud financiera controles de criterios 4/6

Avenue Therapeutics tiene un patrimonio de los accionistas total de $1.7M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $2.6M y $973.0K respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$2.60m
Patrimonio	US$1.65m
Total pasivo	US$973.00k
Activos totales	US$2.63m

Actualizaciones recientes sobre salud financiera

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Mar 19

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Dec 19

Recent updates

Avenue Therapeutics shares slide on pricing $12M securities offering

Oct 07

Avenue Therapeutics up 4% on 1-for-15 reverse stock split

Sep 22

Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine

Jun 14

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($2.6M) de ATXI superan a sus pasivos a corto plazo ($973.0K).

Pasivo a largo plazo: ATXI no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: ATXI está libre de deudas.

Reducción de la deuda: ATXI no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ATXI tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: ATXI tiene menos de un año de cash runway si el flujo de caja libre sigue creciendo a tasas históricas de 16.7% cada año.

Salud financiera de hoja de balance de Avenue Therapeutics

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

the Staff of Nasdaq Determines to Delist Avenue Therapeutics’ Securities from Nasdaq Based Upon its Continued Non-Compliance with the Rule

Avenue Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Avenue Therapeutics Receives Non-Compliance Notice From The Nasdaq Stock Market LLC

Avenue Therapeutics Receives Non-Compliance Letter from Nasdaq

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Recent updates

New major risk - Financial position

Price target increased by 1,500% to US$900

Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

Now 570% overvalued after recent price rise

New major risk - Revenue and earnings growth

Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy

Avenue Therapeutics, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

New major risk - Revenue and earnings growth

the Staff of Nasdaq Determines to Delist Avenue Therapeutics’ Securities from Nasdaq Based Upon its Continued Non-Compliance with the Rule

New major risk - Financial position

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

New major risk - Share price stability

Avenue Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Executive Director recently bought US$251k worth of stock

Avenue Therapeutics, Inc. Announces High Potency and Full Efficacy in A Model of Generalized Seizures for Its Novelgaba-A Receptor Potentiator, Baer-101, Supporting Phase 2 Clinical Study

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc. Reaches Agreement with U.S. Food and Drug Administration on Key Elements of Phase 3 Safety Study for Intravenous Tramadol

Avenue Therapeutics Receives Non-Compliance Notice From The Nasdaq Stock Market LLC

Avenue Therapeutics, Inc. announced that it has received $0.24 million in funding

Avenue Therapeutics, Inc., Annual General Meeting, Dec 28, 2022

Avenue Therapeutics, Inc. (NasdaqCM:ATXI) acquired Baergic Bio, Inc.

Avenue Therapeutics, Inc. Announces Board Resignations

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $27.6 million.

Avenue Therapeutics shares slide on pricing $12M securities offering

Avenue Therapeutics up 4% on 1-for-15 reverse stock split

Avenue Therapeutics, Inc. Submits Type A Meeting Request and Related Briefing Documents to the FDA

Avenue Therapeutics, Inc. Appoints Alexandra Maclean as Chief Executive Officer

Less than half of directors are independent

Avenue Therapeutics, Inc. Announces Management Changes

Avenue Therapeutics Receives Non-Compliance Letter from Nasdaq

Avenue Therapeutics, Inc. Announces CEO Changes

Less than half of directors are independent

Avenue Therapeutics, Inc. Receives an Acknowledgement Letter from the Office of New Drugs of the Food and Drug Administration Regarding Avenue’s August 31, 2021 Formal Dispute Resolution Request

Avenue Therapeutics, Inc.(NasdaqCM:ATXI) dropped from Russell 3000E Index

Forecast breakeven pushed back to 2024

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Avenue Therapeutics, Inc. Resubmits New Drug Application to the U.S. Food and Drug Administration for IV Tramadol

New 90-day high: US$6.93

How Many Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares Do Institutions Own?

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Avenue Therapeutics, Inc. Provides Regulatory Update for IV Tramadol

Avenue Therapeutics issues regulatory update for IV tramadol

Avenue Therapeutics, Inc. Announces Thomas G. Moore to Resign from the Board of Directors of the Company, Effective December 31, 2020

New 90-day low: US$2.95

Avenue Therapeutics, Inc. Receives Complete Response Letter from the FDA for IV Tramadol

New 90-day low: US$4.53

Price target lowered to US$9.00

New 90-day high - US$12.06

New 90-day high - US$11.68

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera